據報康希諾-B(06185.HK)國內新冠疫苗訂單仍有限
據《21財經》報道引述消息指,康希諾生物-B(06185.HK)國內新冠疫苗訂單仍比較有限。對於國內吸入式新冠疫苗訂單情況,消息稱,政策實施到訂單落地還有一定時間,這個也要看各個省市的需求。而且,肌注式和吸入式新冠疫苗這兩個產品會有替代效應。
對於海外吸入式疫苗訂單情況,消息稱,吸入式疫苗於海外目前只有摩洛哥獲得了許可,訂單也在溝通簽署當中,但不會很多,海外目前沒有很大需求。
康希諾H股今日(14日)高開1.06%,最高見91元。半日收報87.45元,回升2.9%,成交441.4萬股,涉資3.82億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.